Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorde Bono, J. S.
dc.contributor.authorMateo, J.
dc.contributor.authorFizazi, K.
dc.contributor.authorSaad, F.
dc.contributor.authorShore, N.
dc.contributor.authorSandhu, S.
dc.contributor.authorChi, K. N.
dc.contributor.authorSartor, O.
dc.contributor.authorAgarwal, N.
dc.contributor.authorOlmos, D.
dc.contributor.authorThiery-Vuillemin, A.
dc.contributor.authorTwardowski, P.
dc.contributor.authorRoubaud, G.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorKang, J.
dc.contributor.authorBurgents, J.
dc.contributor.authorGresty, C.
dc.contributor.authorCorcoran, C.
dc.contributor.authorAdelman, C. A.
dc.contributor.authorHussain, M.
dc.contributor.authoraffiliation[de Bono, J. S.] Inst Canc Res, London, England
dc.contributor.authoraffiliation[de Bono, J. S.] Royal Marsden, London, England
dc.contributor.authoraffiliation[Mateo, J.] Vall dHebron Inst Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Mateo, J.] Vall dHebron Univ Hosp, Barcelona, Spain
dc.contributor.authoraffiliation[Fizazi, K.] Univ Paris Sud, Inst Gustave Roussy, Canc Med Dept, Villejuif, France
dc.contributor.authoraffiliation[Saad, F.] CRCHUM, Ctr Hosp Univ Montreal, Dept Urol, Montreal, PQ, Canada
dc.contributor.authoraffiliation[Shore, N.] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA
dc.contributor.authoraffiliation[Sandhu, S.] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
dc.contributor.authoraffiliation[Chi, K. N.] BC Canc Agcy, Vancouver, BC, Canada
dc.contributor.authoraffiliation[Sartor, O.] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA
dc.contributor.authoraffiliation[Agarwal, N.] Univ Utah NCI CCC, Huntsman Canc Inst, Dept Med, Div Oncol, Salt Lake City, UT USA
dc.contributor.authoraffiliation[Olmos, D.] Spanish Natl Canc Res Ctr CNIO, Prostate Canc Clin Res Unit, Madrid, Spain
dc.contributor.authoraffiliation[Olmos, D.] Hosp Univ Virgen de la Victoria & Reg Malaga, Malaga, Spain
dc.contributor.authoraffiliation[Thiery-Vuillemin, A.] Ctr Hosp Besancon, Med Oncol Dept, Besancon, France
dc.contributor.authoraffiliation[Twardowski, P.] John Wayne Canc Inst, Santa Monica, CA USA
dc.contributor.authoraffiliation[Roubaud, G.] Inst Bergonie, Dept Med Oncol, Bordeaux, France
dc.contributor.authoraffiliation[Ozguroglu, M.] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey
dc.contributor.authoraffiliation[Kang, J.] AstraZeneca, Global Med Dev Oncol, Gaithersburg, MD USA
dc.contributor.authoraffiliation[Burgents, J.] Merck & Co Inc, Oncol Global Clin Dev, Kenilworth, NJ USA
dc.contributor.authoraffiliation[Gresty, C.] AstraZeneca, Global Med Dev Oncol, Cambridge, England
dc.contributor.authoraffiliation[Corcoran, C.] AstraZeneca, Precis Med & Biosamples R&D Oncol, Cambridge, England
dc.contributor.authoraffiliation[Adelman, C. A.] AstraZeneca, Translat Med, Cambridge, England
dc.contributor.authoraffiliation[Hussain, M.] Northwestern Univ, Dept Med, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA
dc.contributor.funderAstraZeneca
dc.contributor.funderMerck
dc.date.accessioned2025-01-07T15:15:26Z
dc.date.available2025-01-07T15:15:26Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.870
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S092375342040866X/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26987
dc.identifier.wosID573469100608
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.numberS508-S508
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleFinal overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía